- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00950261
Efficacy Study for Postoperative Chemoradiation Using Triweekly Cisplatin in Cervical Cancer Patients
Phase II Clinical Trial for Adjuvant Concurrent Chemoradiation Therapy in Post-operative Cervical Cancer Patients
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Cervical carcinoma is one of the most common gynecologic cancers worldwide. The prognosis of cervical cancer is favorable, with around 80-90% 5-year survival rate in early stage disease. However, advanced disease carries a poor prognosis.
The standard postoperative treatment for patients with cervical cancer who had high-risk factors is chemoradiation. Based on the results of five randomized clinical trials, which consistently showed improved survival in patients treated with cisplatin-based CRT, the National Cancer Institute (NCI) of the United States announced that 'Strong consideration should be given to the incorporation of concurrent cisplatin-based chemotherapy with RT in women who require radiation therapy for treatment of cervical cancer' in 1999.
Although recently reported meta-analysis studies also demonstrated improved local control rates and survival with cisplatin-based chemotherapy concurrent to radiation therapy (RT), the optimal cisplatin dose and dosing schedule are still undetermined. Among the previous five randomized clinical trials, two trials performed by the Gynecologic Oncology Group (GOG) used weekly cisplatin 40 mg/m2 while the other three trials used tri-weekly cisplatin at a dosage range of 50 mg/m2 to 75 mg/m2 combined with 5-fluorouracil (5-FU).
Despite the diversity in cisplatin dose and dosing schedules, weekly cisplatin at a dose of 40 mg/m2 concurrent to RT is widely accepted as the standard regimen of CRT because of its convenience, equal effectiveness, and favorable toxicity in comparison to other 5-FU combined regimens.
However, as a result of the GOG 165 study, which was closed prematurely because an interim analysis found that patients in the 5-FU treatment group were not likely to achieve a better outcome, the role of 5-FU (previously popularly included in clinical trials) as a radiosensitizer became subject to debate. Furthermore, a clinical trial performed by the NCI in Canada comparing pelvic RT alone with weekly cisplatin 40 mg/m2 concurrent to RT failed to show improvement of progression free and 5-year survival. While the authors suggested several possible reasons for why their study failed to demonstrate a survival benefit with concurrent weekly cisplatin 40 mg/m2 chemotherapy, other investigators have tried to find another optimal dose and dosing schedule for cisplatin administration.
In light of the results of the previous clinical trial that indicated 5-FU may not be an active radiosensitizer, weekly cisplatin 40 mg/m2 and tri-weekly cisplatin 75 mg/m2 remain the most popular cisplatin doses and dosing schedules. However, despite the possible advantages of tri-weekly cisplatin 75 mg/m2, which offer an increased peak concentration of cisplatin and cisplatin administration during brachytherapy, no clinical trials have efficacy of tri-weekly cisplatin-based chemotherapy concurrent to RT.
Therefore, the investigators are going to perform the efficacy study of postoperative, tri-weekly cisplatin chemoradiation for patients with cervical cancer.
Undersøgelsestype
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Seoul, Korea, Republikken, 139-706
- Korea Institute of Radiological & Medical Sciences
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- cervical cancer
- underwent radical hysterectomy
- non-small cell type
- FIGO stage 1B - 2A
- have one or more risk factors (lymph node involvement, resection margin involvement, parametrial involvement)
- GOG performance status 0 - 2
Exclusion Criteria:
- Previous history of chemotherapy or radiation
- History of other cancer
- Hypersensitivity to platinum agents
- Pregnancy
- Serious medical disease
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: tri-weekly cisplatin
Patients in this arm will postoperatively receive cisplatin 75mg/m2 intravenously every 3 weeks, 3 cycles with radiation
|
cisplatin 75mg/m2 every 3 weeks, intravenous, 3 cycles
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
sygdomsfri overlevelse
Tidsramme: 2 år
|
2 år
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
samlet overlevelse
Tidsramme: 5 år
|
5 år
|
samlet overlevelse
Tidsramme: 2 år
|
2 år
|
sygdomsfri overlevelse
Tidsramme: 5 år
|
5 år
|
all kinds of toxicity
Tidsramme: during treatment
|
during treatment
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Sang-Young Ryu, MD, Korea Institute of Radiological & Medical Sciences
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- KCCH GY 1002
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Cervikale neoplasmer
-
Guangzhou First People's HospitalAfsluttet
-
Xin Jiang, MDUkendt
-
Gangnam Severance HospitalAfsluttetAnterior Cervical Discectomy and Fusion (ACDF) kirurgiKorea, Republikken
-
University of ArkansasAfsluttetAnterior Cervical Discectomy and Fusion (ACDF)Forenede Stater
-
Cleveland Clinic Akron GeneralRekrutteringSmerte | Overfladisk Cervical Plexus BlockForenede Stater
-
AxioMed Spine CorporationUkendtSymptomatisk Cervical Degenerative Disc Disease (DDD) Fra C3-C7Tyskland, Schweiz
-
Qilu Pharmaceutical Co., Ltd.RekrutteringMETASTATISK CERVICAL CANCERKina
-
Orthofix Inc.AfsluttetDegenerativ diskussygdom | Vertebralt Cervical Fusion SyndromeForenede Stater
-
Istanbul Medeniyet UniversityAktiv, ikke rekrutterendeDiafragmatisk lammelse | Frenisk nervelammelse | Anterior suprascapular nerveblok | Overfladisk Cervical Plexus BlockKalkun
-
Antiva BiosciencesAfsluttetLivmoderhalskræft | Human Papilloma Virus | HSIL, højgradige pladeepitellæsioner | Cervikal dysplasi | HSIL af Cervix | Højgradig cervikal intraepitelial neoplasi | HIV negativ | CIN - Cervical Intraepithelial Neoplasia | Cervikal neoplasmaSydafrika
Kliniske forsøg med tri-weekly cisplatin
-
University of California, Los AngelesAfsluttetStress, psykologisk | Angst | Depressive symptomerForenede Stater
-
Korea Cancer Center HospitalAsan Medical Center; Seoul National University Hospital; Gangnam Severance...RekrutteringLivmoderhalskræftKorea, Republikken, Kina, Thailand, Vietnam
-
Federal University of São PauloInstituto Paulista de Estudos e Pesquisa em Oftalmologia; Eye Clinic Day...Afsluttet
-
Pusan National University HospitalErbe USA IncorporatedRekruttering
-
Regional Hospital HolstebroAfsluttet
-
University Hospital, GenevaUkendtKoronararteriesygdomSchweiz
-
Institut de Recherche pour le DeveloppementMedical Research Council; Institut Pasteur; Centre Muraz; REVS PLUS Burkina... og andre samarbejdspartnereIkke rekrutterer endnu
-
Galderma R&DAfsluttetMelasmaBrasilien, Mexico
-
Institute for Biomechanics, ETH ZürichAfsluttetGenoptræning efter ankelskaderSchweiz
-
University Health Network, TorontoAfsluttetThyroidneoplasmer | Kræft i skjoldbruskkirtlen | Thyroid NoduleCanada